Essa Pharma initiates Phase 2 study of masofaniten/enzalutamide combo

Essa Pharma (EPIX) announced the initiation of the Phase 2 portion of its Phase 1/2 study evaluating its lead candidate, masofaniten, a first-in-class N-terminal domain androgen receptor inhibitor, in combination with Astellas (ALPMY) and Pfizer’s (PFE) antiandrogen enzalutamide in patients with metastatic castration-resistant prostate cancer naive to second-generation antiandrogens. Updated results from the first four cohorts of patients from the Phase 1 dose escalation portion of the Phase 1/2 study have been selected for a poster presentation at the upcoming European Society of Medical Oncology Congress taking place October 20-24, 2023, in Madrid, Spain.